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Neuroblastoma is a childhood tumor of the peripheral nervous system that
remains largely uncurable by conventional methods. Mannitol induces apoptosis
in neuroblastoma cell types and insulin-like growth factor I (IGF-I) protects these
cells from hyperosmotic-induced apoptosis by affecting apoptosis-regulatory pro-
teins. In the current study, we investigate factors that enable SH-SY5Y neuroblas-
toma cells to survive in the presence of an apoptotic stimulus. When SH-SY5Y
cells are exposed to high mannitol concentrations, more than 60% of the cells are
apoptotic within 48 h. Normal CS prevents hyperosmotic-induced apoptosis in a
dose-dependent manner, with 0.6% CS protecting 50% of the cells, and 3% CS
rescuing more than 70% of the cells from apoptosis. Serum also delays the
commitment point for SH-SY5Y cells from 9 h to 35 h. A survey of several growth
factors, including epidermal growth factor (EGF), platelet-derived growth factor
(PDGF), nerve growth factor (NGF), fibroblast growth factor (FGF), and IGF-I
reveals that IGF-I is a component of serum necessary for protection of neuroblas-
toma cells from death. Mitochondrial membrane depolarization occurs in greater
than 40% of the cells after mannitol exposure and caspase-3 activation is in-
creased in high mannitol conditions after 9 h. IGF-I blocks both the mitochondrial
membrane depolarization and caspase-3 activation normally induced by hyper-
osmotic treatment in neuroblastoma cells. Our results suggest that (1) IGF-I is a
key factor in serum necessary for protection from death and (2) IGF-I acts
upstream from the mitochondria and the caspases to prevent apoptosis in human
neuroblastoma. J. Cell. Physiol. 182:24–32, 2000. © 2000 Wiley-Liss, Inc.
Neuroblastoma is a tumor that arises from primor-
dial neural crest cells which form the sympathetic ner-
vous system, including the adrenal medulla and the
spinal sympathetic ganglia (Castleberry, 1997; Cianfa-
rani and Rossi, 1997). Although the pathogenesis of
neuroblastoma is unknown, one hypothesis is that im-
proper differentiation of the neural crest cells gives rise
to malignant tumors (Castleberry, 1997). Neuroblastic
tumors account for 8%–10% of all childhood cancers,
with most cases detected in children younger than 10
years of age (Castleberry, 1997). Neuroblastomas are
enigmatic in that some tumors spontaneously regress,
while others, particularly in children over the age of 1,
progress even under a rigorous treatment regimen
(Brodeur et al., 1997; Cianfarani and Rossi, 1997; Na-
kagawara et al., 1997).
Several cloned tumor lines from individual patients
are studied to understand neuroblastoma biology bet-
ter (Ciccarone et al., 1989). One such line, SK-N-SH,
was subcloned into two different lines, SH-SY5Y and
SHEP (Biedler et al., 1988). These two subcloned lines
have distinct features: SH-SY5Y cells are neuron-like,
will grow in mitogen-free media, exhibit anchorage-
dependent growth (Biedler et al., 1988), and express
both insulin-like growth factor II (IGF-II) and func-
tional type I IGF receptor (IGF-IR) (Leventhal et al.,
1995; Martin et al., 1993a, 1993b); SHEP cells require
serum for growth, are anchorage dependent, do not
express IGF-II, and express very little IGF-IR (Biedler
et al., 1988; Leventhal et al., 1995).
Recently, apoptosis has emerged as an important
aspect of normal development (Gelbard et al., 1997;
Jacobson et al., 1997) and tumor biology (reviewed in
Hickman, 1992; Kerr et al., 1994; Martin and Green,
1995; Schulte-Hermann et al., 1994). Apoptosis is a
type of cell death distinct from necrosis and is charac-
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terized by morphological features such as membrane
blebbing, chromatin condensation, and DNA fragmen-
tation (Pittman et al., 1993). Apoptosis in tumor cells
occurs spontaneously near areas of necrosis, as well as
in response to radiation and chemotherapeutic drug
exposure, the classic cancer therapy regimen (Kerr et
al., 1994). Interference with the apoptotic pathway
may give tumor cells, including neuroblastoma, a sur-
vival advantage as well as conferring on them resis-
tance to drug therapy (Gelbard et al., 1997; Hickman
1992).
Growth factors can block apoptosis, and in turn,
serve as survival factors during normal nervous system
development. Nerve growth factor (NGF) is essential
for the survival of sympathetic neurons (Deshmukh
and Johnson, 1997; Cameron et al., 1991; Vogelbaum et
al., 1998), and epidermal growth factor (EGF) and
platelet-derived growth factor (PDGF) can regulate
central nervous system and neural crest cell develop-
ment, respectively (Kornblum et al., 1998; Soriano
1997). Growth factors or growth factor receptors also
protect neuroblastoma cells from cell death, contribut-
ing to abnormal growth and resistance to treatment.
NGF blocks apoptosis in primary neuroblastoma (Na-
kagawara and Brodeur, 1997). NGF can also protect
SK-N-SH neuroblastoma cells from chemotherapy in-
duced apoptosis (Falcione et al., 1993) while PDGF
prevents murine neuroblastoma cells from undergoing
apoptosis upon serum withdrawal (Funa and Ahgren,
1997), and FGF delays apoptosis in human glial cell
tumors (Murai et al., 1996).
We are interested in the role of IGF-I, IGF-II, and
IGF-IR in neuroblastoma tumorigenesis. Similar to
other growth factors, the IGFs protect neuronal cells
from apoptosis and contribute to tumor growth and
resistance to treatment (O’Connor, 1998). SH-SY5Y
and SHEP human neuroblastoma cells undergo apo-
ptosis when grown in hyperosmotic media and IGF-I is
neuroprotective (Cheng and Feldman, 1998; Matthews
and Feldman, 1996; Matthews et al., 1997; Singleton et
al., 1996b). New protein synthesis is not required for
either of these processes (Matthews et al., 1997). Large
DNA fragments are formed within 1 h of hyperosmotic
exposure, the cells are committed to die at 12 h, and
small DNA fragments are detected at 24 h (Matthews
and Feldman 1996; Matthews et al., 1997). Hyperos-
motic stress also decreases the protein expression of
two bcl family members, Bcl-2 and Bcl-XL (Singleton et
al., 1996a). In these same studies, IGF-I prevents ap-
optosis, maintains Bcl-2 and Bcl-XL levels, and pre-
vents caspase-3 and caspase-7 activation (Matthews et
al., 1997; Singleton et al., 1996a).
In the current study, the ability of growth factors
other than IGF-I to rescue SH-SY5Y human neuroblas-
toma cells from hyperosmotic-induced apoptosis was
investigated. The protective effects of several growth
factors were compared to IGF-IR-mediated protection.
Under conditions of hyperosmotic-mediated death,
IGF-I affords more neuroprotection than the neurotro-
phins, FGF or EGF. This neuroprotection is due, in
part, to the ability of IGF-I to regulate changes in
mitochondrial membrane potentials and to block
caspase activation. These data further support the piv-




Tissue culture plastic was purchased from Corning
(Corning, NY). Dulbecco’s Modified Eagle’s Medium
(DMEM), Hank’s Balanced Salt Solution (HBSS), and
calf serum (CS) were purchased from Gibco BRL
(Gaithersburg, MD). IGF-I was provided by Cephalon,
Inc. (West Chester, PA) and stored in 10 mM acetic acid
at 280°C. All other chemicals were purchased from
Sigma Chemical Company (St. Louis, MO).
Cell culture
SH-SY5Y human neuroblastoma cells were grown in
DMEM plus 10% CS at 37°C in a humidified atmo-
sphere with 10% CO2. Cells were routinely subcultured
after removing the cells from the plates with trypsin-
EDTA (Gibco BRL).
Flow cytometry
Cells were plated at 1 3 105 cells/cm2 density in
6-well plates. After cells reached near confluence
(about 2 d), cells were placed in serum-free media for
4 h before exposure to experimental conditions. At ap-
propriate time periods, cells were lifted from the plates
with trypsin-EDTA. The trypsinized cells and culture
media containing any detached cells were combined,
washed in HBSS without Ca21 or Mg21, fixed using
ice-cold 70% ethanol, and stored at 4°C. Fixed cells
were rinsed in HBSS without phenol red and stained
2–12 h with 18 mg/ml propidium iodide containing 40
mg/ml RNase A at 4°C. Propidium iodide intercalates
into the DNA, allowing total DNA content to be mea-
sured for each cell. The cells can then be placed into
each phase of the cell cycle based on DNA content.
Apoptotic cells characteristically have DNA that is
fragmented into 180–200 base pair fragments. These
fragments are then represented as a sub-GO peak on
the cell cycle histogram. Data were measured and col-
lected on an Epics Elite flow cytometry system (Coulter
Cytometry, Hialeah, FL). The percent apoptotic cells in
all flow cytometry experiments represents the %
sub-GO DNA content.
Bisbenzimide staining
Bisbenzimide is a nuclear stain that gives a clear
representation of nuclear morphology. Cells were
grown in DMEM supplemented with 10% CS on glass
coverslips. After treatment, cells were fixed in 4% para-
formaldehyde for 15 min, rinsed in phosphate-buffered
saline (PBS0, and stained with 1 mg/ml bisbenzimide in
PBS for 30 min. After staining, coverslips were rinsed
in PBS and mounted onto slides. Cells were viewed
under ultraviolet illumination on a Leitz Orthoplan
microscope (Leica Microsystems Inc., Deerfield, IL).
Western blotting
Western blot analyses were performed as previously
described (Leventhal et al., 1995). Equal amounts of
protein (70 mg) were loaded in each experiment. To
verify protein transfer, nitrocellulose membranes were
stained with Ponceau S. Mouse monoclonal antibodies
to Bcl-2 and horseradish peroxidase conjugated second-
ary antibodies were purchased from Santa Cruz Bio-
technology, Santa Cruz, California. Anticaspase-3
25IGF-I PROTECTS NEUROBLASTOMA CELLS
polyclonal antibody was purchased from Pharmingen
(San Diego, CA). Nitrocellulose membranes were incu-
bated with primary antibody (1:1000 dilution) for 2 h,
incubated with secondary antibody (1:2000) for 1 h,
developed with enhanced chemiluminescent Western
blotting detection system (ECL) (Amersham, Arlington
Heights, IL), and exposed to film (Hyperfilm-ECL, Am-
ersham). Blots shown are one of at least three indepen-
dent experiments performed.
Rh123 fluorescence
Rhodamine 123 (Rh123) is a vital dye that is prefer-
entially taken up by the mitochondria. Loss of RH123
fluorescence indicates a loss of mitochondrial mem-
brane potential. Cells were treated for flow cytometry
as described above. After 18 h of treatment, cells were
exposed to 5 mg/ml Rh123 in HBSS for 30 min at 37°C.
Cells were then lifted from the plate with trypsin-
EDTA, stained with propidium iodide as described
above, and immediately read on the flow cytometer.
Results shown are the percent of viable (propidium
iodide excluding) cells that have a Rh123 fluorescence
lower than control levels.
Statistical analyses
All data presented graphically are means of at least
three separate experiments shown 6SEM. Data were
analyzed using a Welch’s nonparametric unpaired t
test unless otherwise indicated.
RESULTS
Serum rescues SH-SY5Y cells from apoptosis
We have previously shown that SH-SY5Y cells sur-
vive under serum-free conditions and that the percent
of cells undergoing apoptosis is similar in the presence
or absence of serum (Singleton et al., 1996b). However,
on addition of mannitol to serum-free media, the cells
detach from the plate and display the characteristics of
apoptosis (Matthews and Feldman, 1996). Mannitol
was chosen as a pro-apoptotic compound in our exper-
iments because it can enhance the therapeutic effec-
tiveness of chemotherapy drugs (Neuwelt and Rap-
oport, 1984; Neuwelt et al., 1986). Although the
concentrations of mannitol needed to produce apoptosis
in vitro are well beyond physiological levels, in vivo
hyperosmolar changes in the tumor microenvironment
could aid in inducing apoptosis, particularly if those
hyperosmolar changes cause mitochondrial damage
and/or changes in Bcl protein expression.
As a starting point for our investigation of which
growth factors other than IGF-I serve as survival fac-
tors for SH-SY5Y cells, we examined the ability of
normal CS to rescue these cells from apoptosis. CS
contains a wide variety of growth factors and cytokines
that enhance the growth of cells in culture. On expo-
sure to 300 mM mannitol, 37% of SH-SY5Y cells be-
come apoptotic by 24 h (Fig. 1A). After 48 h of hyper-
osmotic exposure, 64% of the cells undergo apoptosis,
and the number of dying cells increases to over 70% at
72 and 96 h (Fig. 1A). Morphological changes charac-
teristic of apoptosis, such as membrane blebbing and
chromatin condensation, are present using light or
transmission electron microscopy in these cells after
48 h of exposure to 300 mM mannitol (data not shown).
After establishing that mannitol induces apoptotic
death in SH-SY5Y cells, CS was added into the media
to see if apoptosis would be prevented. When 10% CS is
added into solution, 80% of those cells are protected
from hyperosmotic-induced death, with only 9% of the
cells undergoing apoptosis after 2 d (Fig. 1A). This
protective effect is seen even after 4 d, when more than
75% of the cells are apoptotic in 300 mM mannitol,
whereas apoptotic cells in 300 mM mannitol plus CS
are near control levels. When 10% CS is present, no
morphologically apoptotic cells are seen, although cells
do appear shrunken compared to cells in DMEM alone
or cells in DMEM plus 10% CS. Cells exposed to hyper-
osmotic media with CS added appeared no different
ultrastructurally from those in isotonic media as exam-
ined by electron microscopy (data not shown).
To determine an effective dose of CS for protection of
SH-SY5Y cells against apoptosis, increasing concentra-
tions of CS were added to cells in either isotonic or
hyperosmotic media (Fig. 1B). Once again, cells in iso-
tonic media are viable throughout the experiment.
However, in hyperosmotic media, the percentage of
cells is significantly increased; 34% of cells are apopto-
tic by 24 h in 300 mM mannitol with no CS present
versus 2% in DMEM. Increasing concentrations of CS
results in a dose-dependent rescue of the cells. After
24 h, more than 50% of the cells are protected from
apoptosis with 1% serum, while approximately 80% of
cells are rescued by 3% serum. There is little difference
in rescue at concentrations above 3%; however, the
remainder of experiments in this study were performed
using 10% serum to ensure maximum protective effects
over time courses longer than 48 h.
To determine the time point at which hyperosmotic-
exposed SH-SY5Y cells are committed to die, serum
deprived cells were exposed to 300 mM mannitol. Ten
percent CS was added at time periods between 0 and
48 h. After 48 h of exposure, cells were prepared for
flow cytometry and stained with propidium iodide (Fig.
1C). We did not observe one distinct point after which
rescue with serum was unachievable. Rather, the num-
ber of apoptotic cells increases in an almost linear
fashion as the time increases between hyperosmotic
exposure and serum addition. When serum is present
at the time of exposure to mannitol, 8% of the cells
undergo apoptosis (Fig. 1C). The percentage of apopto-
tic cells increases steadily over the course of the exper-
iment. The point at which 50% of the cells are apoptotic
is at approximately 35 h. To verify that this delay in
commitment point was due to the addition of CS, a
study was performed in which cells were exposed to 300
mM mannitol at time 0, and at the indicated time
points, mannitol was removed and replaced by DMEM
(isotonic media). When hyperosmotic media is replaced
by isotonic media, the point at which 50% of cells die is
between 9 h and 12 h (Fig. 1d). Therefore, serum has
the ability to prolong the commitment point after
which time the apoptotic program cannot be reversed.
IGF-I is a major component of serum that
protects cells from apoptosis
Serum contains many different growth factors and
cytokines that play a protective role in other cell types.
To investigate which of these factors are antiapoptotic
in neuroblastoma cells, different growth factors were
surveyed for their ability to block DNA fragmentation
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as measured by flow cytometry. Growth factors in-
cluded in this survey were IGF-I, EGF, acidic fibroblast
growth factor (aFGF), basic fibroblast growth factor
(bFGF), NGF, and PDGF, in addition to serum itself.
The only growth factor tested that produced an effect
similar to serum is IGF-I; IGF-I and 1% CS both re-
duced the amount of cells undergoing apoptosis from
67% to 28% and 25% (P , 0.005), respectively, after
48 h of exposure (Fig. 2). Ten percent CS significantly
(P 5 0.0005) reduces the number of apoptotic cells to
less than 10%. The concentration of IGF-I in this lot of
CS as measured by radioimmunoassay was 3.6 nM in
10% CS, which is well below the 10 nM IGF-I used in
all of the experiments in this study. Therefore, the
greater protective effect elicited by CS is not due solely
to IGF-I levels. The only other growth factor to produce
an effect was EGF, which reduces the percentage of
apoptotic cells from 67% to 44%. The difference be-
tween EGF and any other treatment was not statisti-
cally significant, however, indicating that EGF rescues
Fig. 1. A: Serum rescues SH-SY5Y cells from hyperosmotic-induced
apoptosis. Cells were serum starved overnight, then exposed to either
Dulbecco’s Modified Eagle’s Medium (DMEM) 6 10% calf serum (CS)
or 300 mM mannitol 6 10% CS. At the times indicated, cells were
prepared for flow cytometry and stained with propidium iodide. By
48 h, mannitol significantly increases the percentage of apoptotic cells
as determined by analysis of variance (ANOVA), and 10% CS returns
the number of apoptotic cells to control levels. The values listed are
mean 6 SEM for three separate experiments. An asterisk (p) means
the value is statistically significant (P , 0.01) compared with DMEM
at time 0. A double asterisk (pp) means the value is statistically
significant (P , 0.01) compared to 300 mM mannitol for that time
point. B: Serum rescues neuroblastoma cells in a dose-dependent
manner. Serum starved cells were exposed to DMEM or 300 mM
mannitol and 0%, 0.6%, 15, 3%, or 10% CS. After 24 h, cells were
prepared for flow cytometry and stained with propidium iodide. Ad-
dition of 1% CS or greater decreases the number of apoptotic cells to
levels statistically similar to controls. The values shown are mean 6
SEM for three separate experiments. An asterisk (p) means the value
is statistically significant (P , 0.01) compared with 300 mM mannitol.
C: Determination of serum rescue point. Serum-deprived cells were
exposed to 300 mM mannitol at time 0. At the indicated times, the
solution was removed from the cells and replaced by 300 mM mannitol
plus 10% CS. After 48 h of exposure, cells were prepared for flow
cytometry and stained with propidium iodide. Values given are
mean 6 SEM for three separate experiments. D: Determination of
isotonic rescue point. SH-SY5Y cells were serum deprived overnight,
then exposed to 300 mM mannitol. At the indicated times, the solution
was aspirated from the cells, and fresh DMEM was added to the wells.
48 h postexposure, the cells were collected, prepared for flow cytom-
etry, and stained with propidium iodide. Values given are the mean 6
SEM for three separate experiments.
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SH-SY5Y cells from hyperosmotic-induced apoptosis at
an intermediate level. None of the other growth factors
tested protect SH-SY5Y cells from apoptosis induced by
hyperosmolar stress. SH-SY5Y cells produce endoge-
nous IGF-II, which can also activate the IGF-IR (Mar-
tin and Feldman 1993; Martin et al., 1993). However,
studies using a-IR3, a blocking antibody for the IGF-
IR, indicate that endogenous IGF-II production does
not play a role in protecting these cells from hyperos-
motic-induced apoptosis. In hyperosmotic conditions,
the percentage of apoptotic cells after 24 h was 40.3%;
when a-IR3 was present, the percentage of apoptotic
cells was 36% (data not shown). Because endogenous
IGF-II had no effect on protection of these cells, exog-
enous IGF-II was not included in the growth factor
survey.
To support the importance of IGF-I as a serum com-
ponent necessary for neuroblastoma survival, morpho-
logical characteristics of SH-SY5Y cells were examined
under different conditions using bisbenzimide to stain
the nuclei of the cells. Cells in isotonic media appear
normal with or without serum or IGF-I present (Fig. 3
A, B, C). On addition of 300 mM mannitol for 24 h,
fragmented nuclei are seen, with a dramatic decrease
in cell density (Fig. 3D). When serum or IGF-I is added
to the media, the number of fragmented nuclei dramat-
ically decreases, and the cell viability increases greatly
(Fig. 3E, F). Based on the results above, we conclude
that IGF-I is the growth factor most effective in pre-
venting hyperosmotic-induced apoptosis. Therefore,
the remainder of our experiments focused on under-
standing the mechanism whereby IGF-I prevents man-
nitol-mediated apoptosis in SH-SY5Y cells.
IGF-I prevents mitochondrial membrane
depolarization induced by hyperosmotic stress
Changes in mitochondrial function play a pivotal role
in several aspects of apoptosis. We investigated the
effects of hyperosmotic stress and IGF-I addition on
mitochondrial membrane potential as a measure of
mitochondrial function. Mitochondria are depolarized
when SH-SY5Y cells are exposed to increasing concen-
trations of mannitol. As the environment becomes
more hyperosmolar, more cells undergo apoptosis (Fig.
4A). Significant (P , 0.01) increases in apoptosis are
not seen until the mannitol level exceeds 200 mM. A
similar result is seen when Western blot analysis is
performed for activated caspase-3 (data not shown).
Mitochondrial membrane depolarization is detected at
an earlier time point than DNA fragmentation. At 18 h
posttreatment, the mitochondrial membrane is depo-
larized in approximately 45% of SH-SY5Y cells exposed
to 300 mM mannitol, versus 23% of cells in DMEM
alone (Fig. 4B). Next, 10 nM IGF-I is added to the
media, and the mitochondrial membrane potential is
studied. In the presence of IGF-I, the number of cells
showing mitochondrial membrane depolarization is
very similar to control (Fig. 4B).
Caspase-3 is activated by hyperosmotic stress
and is prevented by IGF-I in SH-SY5Y cells
Caspase-3 activation is one of the later events in the
apoptotic cascade and is necessary for apoptosis to
occur in many systems (Janicke et al., 1998; Woo et al.,
1998). Activation of effector caspases is downstream
from the regulation point of the Bcl proteins and the
events that occur at the mitochondria (Chinnaiyan et
al., 1996; Zha et al., 1996). In the current study we
examined the time course of caspase-3 activation in
SH-SY5Y cells. Caspase-3 is cleaved from a 32 kDa
protein into 17 and 14 kDa products to become active.
These activation bands can be detected through West-
ern immunoblotting in all conditions, but increase in
intensity after 9 h of hyperosmotic stress, with cleav-
age products detected through 24 h (Fig. 5A). A similar
pattern is observed for caspase-7, another effector
caspase thought to act parallel to caspase-3 (data not
shown). Next, caspase activation was examined in the
absence or presence of IGF-I after 3 or 6 h of exposure
to 300 mM mannitol. No cleavage products are detected
in control conditions. Activation bands are again seen
when cells are exposed to hyperosmotic media. As
predicted, IGF-I addition blocks caspase-3 cleavage
(Fig. 5B). A similar pattern was again observed for
caspase-7 (data not shown). Together these data sug-
gest that hyperosmotic-induced apoptosis is a caspase-
dependent form of apoptosis. IGF-I acts to prevent
caspase activation, either through direct or indirect
interference with the caspase cascade.
DISCUSSION
Because neuroblastoma is resistant to many types of
therapy, we are interested in determining the factors
Fig. 2. Comparison of the rescue ability of a variety of growth
factors. SH-SY5Y cells were placed in serum free media overnight,
then exposed to 300 mM mannitol 6 1% calf serum (CS), 10% CS, 10
nM insulin-like growth factor I (IGF-I), 10 ng/ml epidermal growth
factor (EGF), 10 ng/ml acidic fibroblast growth factor (aFGF), 10
ng/ml basic fibroblast growth factor (bFGF), 10 ng/ml nerve growth
factor (NGF), or 10 ng/ml platelet-derived growth factor (PDGF). After
48 h, cells were prepared for flow cytometry and stained with pro-
pidium iodide. The difference between IGF-I or 1% CS and 300 mM
mannitol was statistically significant (P , 0.005). The difference
between 10% CS and 300 mM mannitol was statistically extremely
significant (P 5 0.0005). The values shown are the mean 6 SEM for
three separate experiments. An asterisk (p) means the value is sta-
tistically significant (P , 0.01) compared with 300 mM mannitol.
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that enhance neuroblastoma cell survival. We have
previously reported that IGF-I protects neuroblastoma
from apoptosis (Matthews and Feldman, 1996; Mat-
thews et al., 1997; Singleton et al., 1996a,b). In the
current study, we examined the potential role of other
growth factors in neuroblastoma survival and com-
pared the protective effects of these growth factors to
IGF-I.
We began by investigating the ability of CS to rescue
neuroblastoma cells from hyperosmotic-induced apo-
ptosis. CS contains a wide variety of factors known to
protect cells from death, including IGF-I. We found
that CS protects SH-SY5Y cells from hyperosmotic
shock in a dose-dependent manner, with as little as 1%
CS exerting a protective effect. CS also delays the point
at which cells are committed to die. In our experiments,
CS protects neuroblastoma cells from apoptosis better
than IGF-I alone. These data led us to examine the
ability of growth factors, other than IGF-I, to block
hyperosmotic-mediated apoptosis.
In SH-SY5Y neuroblastoma cells, other growth fac-
tors had little or no protective effect when compared to
IGF-I. These data are interesting in light of several
reports of the neuroprotective effects of these growth
factors in neuroblastoma. NGF promotes survival and
differentiation of early stage and stage 4S neuroblas-
toma tumors (Nakagawara and Brodeur, 1997). NGF
also prevents neocarzinostatin-induced apoptosis in
SK-N-SH cells, the line from which SH-SY5Y cells were
derived (Falcione et al., 1993). PDGF can rescue NB41
neuroblastoma cells from apoptosis induced by serum
withdrawal and 6-hyproxydopamine (Funa and Ah-
gren, 1997). Although FGF only promotes proliferation
and enhances phorbol ester-induced differentiation in
SH-SY5Y cells (Janet et al., 1995; Lavenius et al.,
1994), it does protect U-87MG and U-251UG glioma
cells (Murai et al., 1996), as well as NIH3T3 cells
(Wieder et al., 1997) from apoptosis.
Clearly, these data suggest that neuroblastoma cell
lines display distinct patterns of growth factor medi-
ated survival. While SH-SY5Y cells express Trk A re-
ceptors, the primary response of these cells to NGF is
differentiation (Lavenius et al., 1995; Poluha et al.,
1995), not survival. SH-SY5Y cells undergo terminal
differentiation with continuous NGF exposure; once
differentiated, these cells are then dependent on NGF
for protection from apoptosis (Jensen et al., 1992).
These data suggest that NGF is not important for
survival in undifferentiated SH-SY5Y cells, and may
actually enhance apoptosis in these cells by mediating
a more differentiated phenotype. SH-SY5Y cells also
express the low affinity NGF receptor p75 (Ehrhard et
al., 1993). The p75 receptor has pro-apoptotic activity
in response to NGF treatment in SK-N-BE and SK-
N-MC neuroblastoma cells (Bunone et al., 1997; Kuner
and Hertel, 1998). Therefore, NGF could actually en-
hance apoptosis rather than prevent it in SH-SY5Y
cells.
SH-SY5Y cells also express functional PDGF recep-
tors, and PDGF stimulates both proliferation and dif-
ferentiation in these cells (Janet et al., 1995; Pahlman
et al., 1992). A similar effect on SH-SY5Y cells is seen
with FGF (Janet et al., 1995; Lavenius et al., 1994).
FGF can increase the expression of p75NTR in CHP100
human neuroblastoma cells as well (Taiji et al., 1992),
which as mentioned previously, could actually promote
apoptosis. EGF can enhance [3H]-thymidine uptake in
SK-N-SH, but not SH-SY5Y cells, and only in the pres-
ence of fetal bovine serum, suggesting the need for
other serum factors to produce a proliferative response
(da Motta et al., 1997). Collectively, these reports cou-
pled with the findings from the current study, indicate
Fig. 3. A–F: Morphological comparison of serum and insulin-like
growth factor I (IGF-I) rescue. Serum-deprived cells were exposed to (A)
Dulbecco’s Modified Eagle’s Medium (DMEM); (B) DMEM plus 10%
calf serum (CS); (C) DMEM 1 10 nM IGF-I; (D) 300 mM mannitol; (E)
300 mM mannitol plus 10% CS; or (F) 300 mM mannitol plus 10 nM
IGF-I. After 24 h of exposure, cells were fixed, rinsed, and stained
with bisbenzimide. Cells exposed to 300 mM mannitol show frag-
mented nuclei. Representative fields are shown for each condition.
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that while many growth factors play a role in growth
and differentiation of SH-SY5Y cells, IGF-I provides
the most potent protection against apoptosis.
Apoptosis is a complex phenomenon regulated by
many different proteins, any one of which could be
affected by the presence of growth factors. Two major
families of apoptosis regulatory proteins exist: the
Bcl-2 family and the caspase family. Bcl proteins ap-
pear to act upstream from the caspases (Zha et al.,
1996) at the level of the mitochondria. We have shown
that Bcl protein family members can be modulated by
IGF-I (Singleton et al., 1996a). Therefore, we postu-
lated that IGF-I would have an effect on events occur-
ring at the mitochondrial level.
In the current study, we investigated the effects of
hyperosmotic stress and IGF-I addition on the mito-
chondrial membrane potential, as a measure of mito-
chondrial function. Mannitol treatment results in a
concentration dependent increase in the number of
cells with depolarized mitochondria, as well as an in-
crease in DNA fragmentation as measured by flow
cytometry. IGF-I blocks mitochondrial depolarization
and DNA fragmentation. These data suggest that
IGF-I acts upstream of the mitochondria to prevent
apoptosis in neuroblastoma cells. Bcl proteins, includ-
ing Bcl-2 and Bcl-XL, form pores in the outer mitochon-
drial membrane which regulate the mitochondrial per-
meability transition and the release of cytochrome C
and apoptosis-inducing factor (AIF) into the cytosol
(Marzo et al., 1998; Minn et al., 1997; Reed 1997;
Schendel et al., 1997). The changes in mitochondrial
membrane permeability alter membrane polarity.
Cells undergoing apoptosis show a mitochondrial mem-
Fig. 4. A: Mannitol causes DNA fragmentation in SH-SY5Y cells.
Serum-deprived cells were exposed to 0, 20, 50, 100, 200, or 300 mM
mannitol for 48 h, then prepared for flow cytometry. The difference
between 300 mM mannitol and 0 mM mannitol is statistically signif-
icant (P 5 0.0002). Results shown are the mean 6 SEM for three
separate experiments. An asterisk (p) means the value is statistically
significant (P , 0.01) compared with 0 mM Mann. B: Insulin-like
growth factor I (IGF-I) prevents mitochondrial membrane depolariza-
tion in SH-SY5Y cells. Serum-deprived cells were exposed to 0 or 300
mM mannitol 6 IGF-I for 18 h, then incubated with rhodamine 123
(Rh123) for 30 min at 37°C and prepared for flow cytometry. Results
are represented as percentage of propidium iodide excluding cells
with Rh123 fluorescence below control levels. The difference between
300 mM mannitol and Dulbecco’s Modified Eagle’s Medium (DMEM)
is statistically significant (P 5 0.001), and the difference between 300
mM mannitol plus 10 nM IGF-I is significant (P , 0.01). Results are
the mean of three experiments plus SEM. An asterisk (p) means the
value is statistically significant (P , 0.01) compared with DMEM. A
double asterisk (pp) means the value is statistically significant (P ,
0.01) compared to 300 mM mannitol.
Fig. 5. A: The effect of mannitol exposure on caspase-3 activation in
SH-SY5Y cells. Serum-deprived cells were exposed to 300 mM man-
nitol for the times indicated. Whole-cell lysates were collected, run on
a sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gel, and Western immunoblotted using a polyclonal anti-
caspase-3 antibody. Blot shown is one of three performed. B: Insulin-
like growth factor I (IGF-I) prevents caspase-3 activation in SH-SY5Y
cells after hyperosmotic exposure. Cells were exposed to Dulbecco’s
Modified Eagle’s Medium (DMEM) 6 10 nM IGF-I or 300 mM man-
nitol 6 10 nM IGF-I for 6 h. Whole-cell lysates were collected, run on
an SDS-PAGE gel, and Western immunoblotted using a polyclonal
anticaspase-3 antibody. Blot shown is one of three performed.
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brane depolarization which can be prevented by over-
expression of Bcl-XL or Bcl-2, and this depolarization
occurs prior to caspase activation (Susin et al., 1997;
Vander Heiden et al., 1997). Therefore, IGF-I could
prevent mitochondrial membrane depolarization in
SH-SY5Y cells by affecting Bcl protein levels or activa-
tion, in turn preventing pore opening and release of
AIF.
We next investigated the effect of IGF-I on activation
of the more downstream caspases. The caspase family
of proteins are cysteine proteases that are themselves
cleaved to produce active enzymes (Villa et al., 1997).
On activation, the caspases form a proteolytic cascade
that ultimately causes apoptosis (Villa et al., 1997).
Any interference in this cascade can affect the outcome
of an apoptotic stimulus (Goldstein, 1997). We have
previously shown that 24 h of hyperosmotic stress in-
duces activation of two of the caspases, caspase-3 and
caspase-7 (Singleton et al., 1996a). We chose to exam-
ine these two caspases further because they are down-
stream and essential for apoptosis to occur in many
systems. When SH-SY5Y cells are exposed to hyperos-
motic media, caspase-3 cleavage, and therefore activa-
tion, is seen as early as 9 h. This cleavage is prevented
by the addition of IGF-I. Total protein levels of
caspase-3 remain unchanged however, indicating that
regulation of caspase-3 by both hyperosmotic exposure
and IGF-I is by regulating the enzyme activity, not by
regulating protein transcription or translation.
Our data support recent studies suggesting that
IGF-I exerts its protective effect upstream from the
caspases. IGF-I binding to the IGF-IR can activate the
phosphatidylinositol 3-kinase effector Akt/PKB which
in turn phosphorylates the Bcl-2 family member Bad.
Once phosphorylated, Bad can no longer bind Bcl-XL or
Bcl-2 (Zha et al., 1996), allowing these proteins to exert
their protective effect at the mitochondrial level, poten-
tially by blocking the release of cytochrome C, required
for caspase activation (del Peso et al., 1997; Datta et
al., 1997). Currently, we only know that IGF-IR acti-
vation prevents mitochondrial membrane depolariza-
tion and caspase-3 cleavage, events that occur late in
the above cascade. We are now examining the roles of
Akt and Bad phosphorylation in neuroblastoma under
conditions of hyperosmotic induced apoptosis and
IGF-I rescue.
Several questions still remain that need further in-
vestigation. Does hyperosmotic shock affect apoptosis
in other tumor cell types, and does serum rescue these
other cell types as well? Does IGF-I prevent apoptosis
solely through regulation of the Bcl proteins, or are
other mechanisms involved? And finally, does IGF-I
exert any protective effect through direct interference
with the caspase cascade, or does IGF-I only effect
proteins upstream from the caspases? These questions
will be important to answer to understand how manip-
ulating either IGF-I and/or other growth factors might
prove beneficial in treating neuroblastoma.
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